Sign up to save your podcasts
Or
Share Adjuvant BRAF and MEK Inhibition for Melanoma: 'Impressive'
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Adjuvant BRAF and MEK Inhibition for Melanoma: 'Impressive'
New at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows 'impressive' results in relapse-free survival.
View all episodes
By MedscapeNew at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows 'impressive' results in relapse-free survival.